Aclaris Therapeutics, Inc. 8-K

What Happened
On April 28, 2026, Aclaris Therapeutics, Inc. (ACRS) announced positive full top-line results from the first-in-human Phase 1a single‑ascending‑dose (SAD) and multiple‑ascending‑dose (MAD) trial of ATI-052, its anti‑TSLP/IL‑4Rα bispecific antibody. The company also disclosed the selection of lichen planus (LP) as the lead indication for ATI-2138, its selective ITK/JAK3 inhibitor. Aclaris held a conference call the same day to discuss these developments and furnished a presentation (Exhibit 99.1) and a press release (Exhibit 99.2) with the filing.

Key Details

• Date filed: April 28, 2026 (Form 8-K; accession 0001104659-26-049733).
• ATI-052: reported positive full top-line Phase 1a SAD and MAD results (first-in-human).
• ATI-2138: company selected lichen planus as the lead clinical indication going forward.
• Materials: company presentation (Exhibit 99.1) and press release (Exhibit 99.2) were furnished with the 8‑K; conference call held April 28, 2026.

Why It Matters
Positive Phase 1 top-line data is an early clinical milestone that can de‑risk ATI‑052’s development and support planning for later-stage studies. Naming lichen planus as ATI‑2138’s lead indication signals a focused development path and may accelerate protocol design and regulatory interactions. The 8‑K did not include detailed efficacy or safety numbers—investors should review the furnished presentation and press release and listen to the company’s call for full data, timelines, and next steps.